Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Mirati nets $220mm through latest public offering

Executive Summary

Mirati Therapeutics Inc. (oncology) netted $220mm through a public offering of 2.4mm common shares (including the overallotment) at $97. The company plans to use the funds for development of sitravatinib (NSCLC, melanoma, bladder cancer, and other solid tumors), MRTX849 (NSCLC and colorectal cancer (CRC)), and preclinical projects including a KRAS G12D inhibitor for NSCLC, colorectal, and pancreatic cancers.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies